


## Supplementary Materials

Soluble Collectin 11 (CL-11) acts as an immunosuppressive molecule potentially used by stem cell derived retinal epithelial cells to modulate T cell response

Giorgia Fanelli<sup>1\*</sup>, Marco Romano<sup>1</sup>, Giovanna Lombardi<sup>1</sup> and Steven H. Sacks<sup>1</sup>


<sup>1</sup> Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, SE1 9RT, UK.




**Figure S1.** fRPE cell *in vitro* differentiation. **(A)** Phase contrast microscopy showing key morphological changes prior to differentiation (day 1). A cobblestone appearance and homogeneous pigmentation was visible in the RPE cell population by day 30 of cell culture. **(B)** Representative flow cytometry plots showing the gating strategy of fRPE cells used in this study and a representative flow cytometry histograms showing surface expression of CD140b, on fRPE cells treated for 24h under hypoxic conditions or for 3 days with 500 IU of hrIFN $\gamma$ .

A


## PBMCs gating strategy




B



C




D




**Figure S2.** PBMCs gating strategy and co-culture assay with fRPE cells. (A) PBMCs gating strategy to assess cell proliferation of CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets. (B) Representative histogram showing CFSE dilution of gated CD4<sup>+</sup> T cells cultured for 4 days alone or in the presence of fRPE cells pre-treated as indicated. (C) Representative histogram showing CFSE dilution of gated CD8<sup>+</sup> T cells activated with soluble  $\alpha$ CD3

(0.5  $\mu\text{g/mL}$ ) and cultured for 4 days alone or in the presence of fRPE cells pre-treated as indicated. **(D)** Representative plots showing proliferation (CFSE dilution) and CD25 expression of  $\text{CD4}^+\text{CD25}^-$  T cells unstimulated (first row) or stimulated with soluble  $\alpha\text{CD3}$  (0.5  $\mu\text{g/mL}$ ) (second row) in the presence or not of allogeneic dendritic cells (DCs), fRPE cells or fRPE cells and DCs.



**Figure S3.** Uncropped confocal images and CD28 and CL-11 correlation. (A) Representative uncropped confocal images with the selected areas (white rectangle) shown in the main figure of the manuscript (Figure 3A). Cell stained with goat anti-mouse Alexa fluor 488 and goat anti-rabbit Alexa Fluor 546 secondary antibodies alone were used as a control. CD28 (green), CL-11 (red) and Nuclei (blue) are shown. Scale bars represent 50  $\mu$ M. (B) Representative confocal images showing unstimulated cells pre-incubated for 1h at 37°C with 20 $\mu$ g/mL rCL-11 or buffer solution. Uncropped images (scale bars represent 50  $\mu$ M) are on the left with the selected areas (white rectangle) shown in the right panels (scale bars represent 25  $\mu$ M). Quantification of integrated density for CD28 and CL-11 fluorescence using ImageJ software. Data are expressed as mean  $\pm$  SEM. 8 cropped images per condition of a minimum of 20 cells are pooled from three different healthy. \*\* $P < 0.01$  was considered significant using Two-way ANOVA followed by Šídák multiple comparison (Bottom panel). (C) Representative uncropped confocal images with the selected areas (white rectangle) shown in the main figure of the manuscript (Figure 3E). Scale bars represent 50  $\mu$ M. (D) Representative uncropped confocal images with the selected areas (white rectangle) shown in Supplementary Figure 3E. Scale bars represent 50  $\mu$ M. (E) Representative cropped images showing CD28 (green), CL-11 (red) and Nuclei (blue) overlay and CD28 (green) and CL-11 (red) single channels on CD4<sup>+</sup>CD25<sup>-</sup> T cells activated or not with  $\alpha$ CD3/ $\alpha$ CD28 for 48 hours and pre-incubated for 1h at RT with 20 $\mu$ g/mL rCL-11. Scale bars represent 10  $\mu$ M. (F) Statistical analysis for colocalization events of CL-11 and CD28 with Pearson's Correlation Coefficient method (ImageJ software). Data are represented using boxplots indicating the min and max and median.



**Figure S4.** Surface versus Intracellular staining of CD28 and CL-11. **(A)** Representative high magnification images showing CD28 and CL-11 expression by non permeabilised CD4<sup>+</sup>CD25<sup>-</sup> T cells activated with  $\alpha$ CD3/ $\alpha$ CD28 for 48 hours and pre-incubated for 1h at RT with buffer solution (untreated) or rCL-11. CD28 (green), CL-11 (red) and nuclei (blue) are shown. Scale bars represent 25  $\mu$ M. **(B)** Quantification of CD28 mean

fluorescence using ImageJ software. Data are expressed as individual values (28) per condition (Untreated and rCL-11) \* $P < 0.05$  was considered significant using Two Tail Unpaired t test. (C) Representative high magnification cropped images showing CD28 and CL-11 expression by non permeabilised (Upper panels, Surface) and permeabilised (Bottom panels, Intracellular) CD4<sup>+</sup>CD25<sup>-</sup> T cells activated with  $\alpha$ CD3/ $\alpha$ CD28 for 48 hours and pre-incubated for 1h at RT with rCL-11. CD28 (green), CL-11 (red) and nuclei (blue) are shown. Scale bars represent 25  $\mu$ M. (D) Representative graph showing the CD28 and CL-11 mean fluorescence on non permeabilised (surface) and permeabilised (Intracellular) CD4<sup>+</sup>CD25<sup>-</sup> T cells activated as described above.

Supplementary Table S1

| Marker       | Clone       | Fluorochrome         | Supplier      | Cat. No.   |
|--------------|-------------|----------------------|---------------|------------|
| CD4          | OKT4        | Brilliant Violet 605 | BioLegend     | 317438     |
| CD25         | BC96        | PE                   | BioLegend     | 302606     |
| CD25         | BC96        | Brilliant Violet 510 | BioLegend     | 302640     |
| CD3          | UCHT1       | Alexa Fluor 700      | BioLegend     | 300424     |
| CD8          | SK1         | PerCP-Cy5.5          | BD Bioscience | 565310     |
| CD19         | HIB19       | Brilliant Violet 650 | BioLegend     | 302237     |
| CD28         | CD28.2      | APC                  | BioLegend     | 302912     |
| HLA-DR       | L243        | Brilliant Violet 421 | BioLegend     | 307636     |
| HLA-DR       | LN3         | PE-Cy7               | eBioscience   | 25-9965-42 |
| PD-1         | EH12.2H7    | Brilliant Violet 785 | BioLegend     | 329930     |
| HLA-ABC      | W6/32       | APC                  | eBioscience   | 17-9983-42 |
| HLA-ABC      | W6/32       | PerCP-Cy5.5          | BioLegend     | 311420     |
| CD80         | 2D10        | Brilliant Violet 650 | BioLegend     | 305225     |
| CD86         | 2311(FUN-1) | Alexa Fluor 700      | BD Bioscience | 561124     |
| PD-L1        | MIH3        | Brilliant Violet 421 | BioLegend     | 374508     |
| CD140b       | 18A.2       | PE                   | BioLegend     | 323606     |
| IL-10        | JES3-19F1   | PE                   | BioLegend     | 506804     |
| IFN $\gamma$ | 4S.B3       | PE-Cy7               | BioLegend     | 502528     |
| IL-17        | BL168       | Brilliant Violet 421 | BioLegend     | 512322     |
| TNF $\alpha$ | Mab11       | APC                  | BioLegend     | 502912     |